We are thrilled to share the news: MB Therapeutics has secured funding through the Créalia fund. This funding paves the way for the flourishing of the innovation embodied by the MB Therapeutics team.
With the strong support from Créalia, MB Therapeutics is fully committed to advancing its groundbreaking solution dedicated to the automated production of personalized medications using pharmaceutical 3D printing technology. This milestone further solidifies MB Therapeutics’ position as an industry pioneer, determined to revolutionize the way medications are manufactured.
About MB Therapeutics:
Resulting from a close collaboration between Lynxter, a renowned manufacturer of industrial 3D printers, and the University Hospital Center (CHU) of Nîmes, MB Therapeutics emerges as a startup specializing in personalized medicine, harnessing 3D printing technology. This company is committed to revolutionizing treatment administration, particularly for young patients affected by medical conditions, through its innovation in crafting customized pediatric pharmaceutical forms. This advancement is achieved in close partnership with medical experts, showcasing MB Therapeutics’ dedication to health and well-being.